pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
PARItec clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
PARItec projects
8 ClinicalTrials.gov programs sponsored by PARItec.
PARItec has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
APHP 211033
Pari Pharma GmbH
Cardiology and vascular disease
1 trial -
APHP191116
Pari Pharma GmbH
hematologic malignancies ; acute myeloid leukemias
1 trial -
APHP200034
Pari Pharma GmbH
Non-ischemic Dilated Cardiomyopathies
1 trial -
CITY
Pari Pharma GmbH
Cutaneous T-cell lymphomas (CTCL)
1 trial -
Dose dense re-challenge of high dose methotre...
Pari Pharma GmbH
Oncology: RELAPSED PRIMARY CNS LYMPHOMA
1 trial -
MEDITOP/2025/01
Pari Pharma GmbH
Comparative bioequivalence study in healthy volunteers under fasting conditions.
1 trial -
MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension
Pari Pharma GmbH
Familial Hemophagocytic Lymphohistiocytosis (FHL)
1 trial -
SPVN20-CLIN-01
Pari Pharma GmbH
End-stage rod-cone dystrophy
1 trial
Frequently asked questions
How many clinical projects does PARItec have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.